On June 30 2023, ALPHA TEKNOVA ($NASDAQ:TKNO) released its Q2 FY2023 earnings report, showing a total revenue of USD 11.5 million; a 1.4% decrease from the same quarter in the prior year. Net income for the quarter was at USD -7.2 million, slightly worse than that of the previous year at -6.2 million.
On Thursday, June 30th, ALPHA TEKNOVA reported their second quarter earnings results for 2023. The stock opened at $2.6 and closed at $2.8, a 6.9% rise from its previous closing price of $2.6. This was welcome news to investors, as the increase in stock value was a sign of successful business operations. The overall outlook of ALPHA TEKNOVA is positive, with reports showing steady growth quarter over quarter. This growth is attributed to the company’s focus on innovation and developing new products and services that meet customer needs.
The company has also managed to successfully navigate the current economic climate, which has been difficult for other businesses to do. Investors are optimistic about the future of ALPHA TEKNOVA, especially with the second quarter earnings report showing a positive trend. The company’s stock price increase is a sign that investors are confident in the leadership and strategy of the company, as well as its ability to continue to bring in revenue. The successful earnings report is a significant milestone for ALPHA TEKNOVA and provides great potential for further growth in the future. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Alpha Teknova. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Alpha Teknova. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Alpha Teknova. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Alpha Teknova are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
As GoodWhale has done an analysis of ALPHA TEKNOVA‘s financials, we’ve determined that the company is a medium risk investment by our Risk Rating. This rating takes into account both financial and business aspects. Upon further inspection, our risk detection system has detected 2 risk warnings in the balance sheet and cashflow statement of the company. If you’d like to know more about these warnings, please register on our website at goodwhale.com. Our risk warning system is designed to help you make better investment decisions when investing in companies like ALPHA TEKNOVA. More…
Risk Rating Analysis
Star Chart Analysis
The company’s main competitors are Sunshine Biopharma Inc, SCYNEXIS Inc, and Antisense Therapeutics Ltd. All three companies are engaged in the development of new and innovative treatments for various diseases and disorders.
– Sunshine Biopharma Inc ($NASDAQ:SBFM)
Sunshine Biopharma Inc. is a pharmaceutical company that focuses on the development and commercialization of cancer and anti-infective drugs. The company’s market cap is $17.09 million and its ROE is -3.82%. Sunshine Biopharma’s products in development include Adva-27a, a treatment for ovarian and other types of cancer; and Amiket, a treatment for ketamine addiction.
SCYNEXIS Inc is a biopharmaceutical company that focuses on the development and commercialization of novel anti-infectives to address unmet needs in the treatment of serious and life-threatening infections. The company’s lead product, SCY-078, is a novel oral and intravenous (IV) antifungal agent in Phase 3 clinical development for the treatment of vulvovaginal candidiasis (VVC), also known as yeast infection, and invasive fungal infections, such as candidemia and other serious fungal infections.
– Antisense Therapeutics Ltd ($ASX:ANP)
Antisense Therapeutics Ltd is a pharmaceutical company that develops drugs to treat cancer and other diseases. The company has a market capitalization of $66.88 million and a return on equity of -21.12%. Antisense Therapeutics Ltd develops drugs that target the genetic causes of disease. The company’s drugs are designed to silence disease-causing genes. Antisense Therapeutics Ltd’s products are in clinical trials for the treatment of cancer, Huntington’s disease, and amyotrophic lateral sclerosis.
Investors responded positively to ALPHA TEKNOVA‘s second quarter earnings results for fiscal year 2023, despite a slight decrease in total revenue. Net income reported at USD -7.2 million was slightly worse year-on-year, yet the stock price rose on the same day. This suggests that investors may remain confident in the company’s long-term prospects, and are possibly willing to tolerate the short-term losses in order to capitalize on future profitability. A close review of the company’s finances and market performance may be beneficial for investors in order to determine if ALPHA TEKNOVA is a strong investment going forward.